UCB Presents Latest Research from Immunology Portfolio at American College of Rheumatology Annual Meeting Data presentations include:  Positive results from Period 1 of the C-EARLY™ Phase 3 study of CIMZIA® (certol

First Page		Document Content
Date: 2016-01-20 09:39:34 Medicine Clinical medicine Immunology Immunosuppressants RTT Biotechnology Autoimmune diseases Arthritis Certolizumab pegol TNF inhibitor UCB Anakinra		UCB Presents Latest Research from Immunology Portfolio at American College of Rheumatology Annual Meeting Data presentations include:  Positive results from Period 1 of the C-EARLY™ Phase 3 study of CIMZIA® (certol Add to Reading List Source URL: www.ucb-usa.com Download Document from Source Website File Size: 539,51 KB Share Document on Facebook

	UCB Presents Latest Research from Immunology Portfolio at American College of Rheumatology Annual Meeting Data presentations include:  Positive results from Period 1 of the C-EARLY™ Phase 3 study of CIMZIA® (certol DocID: 1rakB - View Document
	JUNE 2015 TABLE OF CONTENTS INTRODUCTION DocID: 1qDC6 - View Document
	TABLE OF CONTENTS INTRODUCTION 2 DocID: 1qs3R - View Document
	TABLE OF CONTENTS INTRODUCTION 2 DocID: 1qius - View Document
	FEBRUARY 2015 TABLE OF CONTENTS INTRODUCTION DocID: 1qcKs - View Document